137 related articles for article (PubMed ID: 21540335)
1. Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice.
Sazani P; Ness KP; Weller DL; Poage D; Nelson K; Shrewsbury AS
Int J Toxicol; 2011 May; 30(3):322-33. PubMed ID: 21540335
[TBL] [Abstract][Full Text] [Related]
2. Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy.
Sazani P; Ness KP; Weller DL; Poage DW; Palyada K; Shrewsbury SB
Int J Toxicol; 2011 May; 30(3):313-21. PubMed ID: 21540336
[TBL] [Abstract][Full Text] [Related]
3. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.
Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K
J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742
[TBL] [Abstract][Full Text] [Related]
4. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
5. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
Malerba A; Thorogood FC; Dickson G; Graham IR
Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
[TBL] [Abstract][Full Text] [Related]
6. Toxicological Characterization of Exon Skipping Phosphorodiamidate Morpholino Oligomers (PMOs) in Non-human Primates.
Carver MP; Charleston JS; Shanks C; Zhang J; Mense M; Sharma AK; Kaur H; Sazani P
J Neuromuscul Dis; 2016 Aug; 3(3):381-393. PubMed ID: 27854228
[TBL] [Abstract][Full Text] [Related]
7. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
Cirak S; Arechavala-Gomeza V; Guglieri M; Feng L; Torelli S; Anthony K; Abbs S; Garralda ME; Bourke J; Wells DJ; Dickson G; Wood MJ; Wilton SD; Straub V; Kole R; Shrewsbury SB; Sewry C; Morgan JE; Bushby K; Muntoni F
Lancet; 2011 Aug; 378(9791):595-605. PubMed ID: 21784508
[TBL] [Abstract][Full Text] [Related]
8. Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy.
Benny Klimek ME; Vila MC; Edwards K; Boehler J; Novak J; Zhang A; Van der Meulen J; Tatum K; Quinn J; Fiorillo A; Burki U; Straub V; Lu QL; Hathout Y; van Den Anker J; Partridge TA; Morales M; Hoffman E; Nagaraju K
J Neuromuscul Dis; 2021; 8(s2):S369-S381. PubMed ID: 34569970
[TBL] [Abstract][Full Text] [Related]
9. Safety pharmacology and genotoxicity evaluation of AVI-4658.
Sazani P; Weller DL; Shrewsbury SB
Int J Toxicol; 2010; 29(2):143-56. PubMed ID: 20110565
[TBL] [Abstract][Full Text] [Related]
10. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
Mitrpant C; Fletcher S; Iversen PL; Wilton SD
J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
[TBL] [Abstract][Full Text] [Related]
11. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
Blain AM; Greally E; McClorey G; Manzano R; Betts CA; Godfrey C; O'Donovan L; Coursindel T; Gait MJ; Wood MJ; MacGowan GA; Straub VW
PLoS One; 2018; 13(6):e0198897. PubMed ID: 29912990
[TBL] [Abstract][Full Text] [Related]
12. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
13. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.
Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Steinhaus JP; Moulton HM; Iversen PL; Wilton SD
Mol Ther; 2007 Sep; 15(9):1587-92. PubMed ID: 17579573
[TBL] [Abstract][Full Text] [Related]
14. Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice.
Desjardins CA; Yao M; Hall J; O'Donnell E; Venkatesan R; Spring S; Wen A; Hsia N; Shen P; Russo R; Lan B; Picariello T; Tang K; Weeden T; Zanotti S; Subramanian R; Ibraghimov-Beskrovnaya O
Nucleic Acids Res; 2022 Nov; 50(20):11401-11414. PubMed ID: 35944903
[TBL] [Abstract][Full Text] [Related]
15. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
Yokota T; Nakamura A; Nagata T; Saito T; Kobayashi M; Aoki Y; Echigoya Y; Partridge T; Hoffman EP; Takeda S
Nucleic Acid Ther; 2012 Oct; 22(5):306-15. PubMed ID: 22888777
[TBL] [Abstract][Full Text] [Related]
16. Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice.
Han G; Gu B; Cao L; Gao X; Wang Q; Seow Y; Zhang N; Wood MJ; Yin H
Nat Commun; 2016 Mar; 7():10981. PubMed ID: 26964641
[TBL] [Abstract][Full Text] [Related]
17. MOTS-c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice.
Ran N; Lin C; Leng L; Han G; Geng M; Wu Y; Bittner S; Moulton HM; Yin H
EMBO Mol Med; 2021 Feb; 13(2):e12993. PubMed ID: 33337582
[TBL] [Abstract][Full Text] [Related]
18. Polyquaternium-mediated delivery of morpholino oligonucleotides for exon-skipping in vitro and in mdx mice.
Wang M; Wu B; Shah SN; Lu P; Lu Q
Drug Deliv; 2017 Nov; 24(1):952-961. PubMed ID: 28633548
[TBL] [Abstract][Full Text] [Related]
19. Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino.
Wu B; Lu P; Cloer C; Shaban M; Grewal S; Milazi S; Shah SN; Moulton HM; Lu QL
Am J Pathol; 2012 Aug; 181(2):392-400. PubMed ID: 22683468
[TBL] [Abstract][Full Text] [Related]
20. Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.
Hara Y; Mizobe Y; Miyatake S; Takizawa H; Nagata T; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():553-564. PubMed ID: 30171567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
